Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ. Coleman DJ, et al. Among authors: alumkal jj. Oncotarget. 2016 Jun 28;7(26):40690-40703. doi: 10.18632/oncotarget.9816. Oncotarget. 2016. PMID: 27276681 Free PMC article.
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Graff JN, et al. Among authors: alumkal jj. Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547. Oncotarget. 2016. PMID: 27429197 Free PMC article. Clinical Trial.
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.
Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. Aggarwal R, et al. Among authors: alumkal jj. Eur Urol Focus. 2016 Dec;2(5):469-471. doi: 10.1016/j.euf.2016.10.011. Epub 2016 Nov 14. Eur Urol Focus. 2016. PMID: 28723508
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.
Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Podolak J, et al. Among authors: alumkal jj. Oncotarget. 2017 Mar 13;8(42):71447-71455. doi: 10.18632/oncotarget.16169. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069718 Free PMC article.
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Wyatt AW, et al. Among authors: alumkal jj. J Natl Cancer Inst. 2017 Dec 1;109(12):djx118. doi: 10.1093/jnci/djx118. J Natl Cancer Inst. 2017. PMID: 29206995 Free PMC article.
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
Sehrawat A, Gao L, Wang Y, Bankhead A 3rd, McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim DH, Sampson DA, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, Alumkal JJ. Sehrawat A, et al. Among authors: alumkal jj. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188. doi: 10.1073/pnas.1719168115. Epub 2018 Mar 26. Proc Natl Acad Sci U S A. 2018. PMID: 29581250 Free PMC article.
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Aggarwal R, et al. Among authors: alumkal jj. J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9. J Clin Oncol. 2018. PMID: 29985747 Free PMC article. Clinical Trial.
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. Nickols NG, et al. Among authors: alumkal jj. Prostate Cancer Prostatic Dis. 2019 Dec;22(4):531-538. doi: 10.1038/s41391-019-0134-5. Epub 2019 Feb 25. Prostate Cancer Prostatic Dis. 2019. PMID: 30804427 Free PMC article.
109 results